First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.
- DOI
- 10.1016/j.eclinm.2021.100797
- Published
- 2021 Apr
- Container
- EClinicalMedicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.eclinm.2021.100797,
title = {First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.},
author = {Falchook G and Infante J and Arkenau HT and Patel MR and Dean E and Borazanci E and Brenner A and Cook N and Lopez J and Pant S and Frankel A and Schmid P and Moore K and McCulloch W and Grimmer K and O'Farrell M and Kemble G and Burris H},
year = {2021},
journal = {EClinicalMedicine},
doi = {10.1016/j.eclinm.2021.100797},
url = {https://doi.org/10.1016/j.eclinm.2021.100797}
}RIS
TY - JOUR TI - First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. AU - Falchook G AU - Infante J AU - Arkenau HT AU - Patel MR AU - Dean E AU - Borazanci E AU - Brenner A AU - Cook N AU - Lopez J AU - Pant S AU - Frankel A AU - Schmid P AU - Moore K AU - McCulloch W AU - Grimmer K AU - O'Farrell M AU - Kemble G AU - Burris H PY - 2021 JO - EClinicalMedicine DO - 10.1016/j.eclinm.2021.100797 UR - https://doi.org/10.1016/j.eclinm.2021.100797 ER -
APA
G, F., J, I., HT, A., MR, P., E, D., E, B., A, B., N, C., J, L., S, P., A, F., P, S., K, M., W, M., K, G., M, O., G, K., & H, B. (2021). First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2021.100797
Source records
- pubmed · retrieved 2026-09-26T08:15:59.104Z